Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
use increased » cases increased (Expand Search), also increased (Expand Search), rate increased (Expand Search)
Showing 201 - 220 results of 48,847 for search '(( significant ((mean decrease) OR (use increased)) ) OR ( significant decrease decrease ))', query time: 0.66s Refine Results
  1. 201
    Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>

    Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

    Published 2025
    “…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …”
    Save to List
    Saved in:
  2. 202
    RcbA and RcbB co-operatively decrease motility independent of CaCl<sub>2</sub> concentration.

    RcbA and RcbB co-operatively decrease motility independent of CaCl<sub>2</sub> concentration. by Shobnom Mustaree (21728815)

    Published 2025
    Save to List
    Saved in:
  3. 203
    Deep crypt secretory (DCS) cells are predominantly distributed in the proximal colon, with a progressive decrease towards the distal colon.

    Deep crypt secretory (DCS) cells are predominantly distributed in the proximal colon, with a progressive decrease towards the distal colon. by Daisuke Sugahara (2047696)

    Published 2025
    Save to List
    Saved in:
  4. 204
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 205
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 206
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 207
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 208
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 209
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 210
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 211
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 212
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 213
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 214
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 215
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 216
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 217
    nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU.

    nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

    Published 2025
    Save to List
    Saved in:
  18. 218
    <i>Porphyromonas gingivalis</i> LPS pretreated by ozone ultrafine bubble water induces decreased TLR2 activation.

    <i>Porphyromonas gingivalis</i> LPS pretreated by ozone ultrafine bubble water induces decreased TLR2 activation. by Mana Endo (22430706)

    Published 2025
    Save to List
    Saved in:
  19. 219
    <i>C</i>. <i>auris</i> induces IL-1Ra in macrophages to decrease the neutrophil function in the skin.

    <i>C</i>. <i>auris</i> induces IL-1Ra in macrophages to decrease the neutrophil function in the skin. by Abishek Balakumar (20189865)

    Published 2024
    Save to List
    Saved in:
  20. 220
    Decreased hypotaurine levels within cells lacking the ADO gene in U251 cells.

    Decreased hypotaurine levels within cells lacking the ADO gene in U251 cells. by Hong Tian (169626)

    Published 2025
    Save to List
    Saved in:

Search Tools: